Pancreatic Tumor Clinical Trials

3 recruiting

Pancreatic Tumor Trials at a Glance

8 actively recruiting trials for pancreatic tumor are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Not Applicable with 3 trials, with the heaviest enrollment activity in Clichy, Brescia, and Brest. Lead sponsors running pancreatic tumor studies include Assistance Publique - Hôpitaux de Paris, Azienda Ospedaliera di Padova, and Abramson Cancer Center at Penn Medicine.

Browse pancreatic tumor trials by phase

Treatments under study

About Pancreatic Tumor Clinical Trials

Looking for clinical trials for Pancreatic Tumor? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pancreatic Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pancreatic Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Not Applicable

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

Liver CancerMelanomaMerkel Cell Carcinoma+9 more
Istituto Oncologico Veneto IRCCS24 enrolled1 locationNCT06753136
Recruiting

Longitudinal, Prospective, French, Multicenter Cohort Study on Pancreatic Radiofrequency

Pancreatic Tumor
GCS Ramsay Santé pour l'Enseignement et la Recherche200 enrolled1 locationNCT05871164
Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Breast CancerLiver CancerEsophageal Cancer+35 more
UMC Utrecht8,000 enrolled18 locationsNCT04075305
Recruiting
Not Applicable

Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors

Hepatocellular Carcinoma (HCC)Gastro-Entero-Pancreatic Tumors (GEPs)
Nantes University Hospital28 enrolled3 locationsNCT07178587
Recruiting
Phase 1

FTT PET/CT in Pancreatic Neuroendocrine Tumors

Pancreatic TumorsNeuroendocrine Carcinoma Metastatic
Abramson Cancer Center at Penn Medicine12 enrolled1 locationNCT07114939
Recruiting

An International Study on Pediatric Patients With Rare Tumors.

MesotheliomaThyroid CarcinomaPleuropulmonary Blastoma+11 more
Azienda Ospedaliera di Padova6,250 enrolled1 locationNCT07072143
Recruiting
Phase 2

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

Gastrointestinal Neuroendocrine Pancreatic Tumor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.90 enrolled1 locationNCT06505395
Recruiting
Not Applicable

METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors

HepatocarcinomaPancreatic Tumor
Assistance Publique - Hôpitaux de Paris300 enrolled1 locationNCT05794048